BECONASE AQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BECONASE AQ (BECONASE AQ).
Glucocorticoid agonist; activates glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins) and suppression of immune cell migration and activation in nasal mucosa.
| Metabolism | Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Major metabolite is inactive. |
| Excretion | Renal: <10% as unchanged drug; biliary/fecal: predominant route, with metabolites excreted in bile and feces; total elimination: >90% as metabolites via feces. |
| Half-life | Terminal elimination half-life of beclomethasone dipropionate (BDP) is approximately 6.5 hours after intranasal administration; active metabolite beclomethasone-17-monopropionate (17-BMP) has a half-life of about 2.7 hours; clinical context: intranasal half-life supports once- or twice-daily dosing. |
| Protein binding | BDP: 87% bound to plasma proteins; 17-BMP: 94-96% bound primarily to albumin. |
| Volume of Distribution | BDP: Vd approximately 20 L/kg (high, indicating extensive tissue distribution); 17-BMP: Vd approximately 10 L/kg; clinical meaning: high Vd suggests wide distribution into tissues, mainly in lungs and nasal mucosa. |
| Bioavailability | Intranasal: Absolute bioavailability is <1% due to low systemic absorption; oral: negligible due to first-pass metabolism (<1%); intranasal delivery results in minimal systemic exposure. |
| Onset of Action | Intranasal: Onset of clinical effect (improvement in nasal symptoms) observed within 12-24 hours after first dose, with maximum benefit after 1-2 weeks. |
| Duration of Action | Intranasal: Duration of action is approximately 24 hours with once-daily dosing; consistent use maintains symptom control. |
| Molecular Weight | 521.07 |
Beclomethasone dipropionate aqueous nasal spray: 1-2 sprays (42-84 mcg/spray) in each nostril twice daily. Total daily dose: 168-336 mcg.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific recommendations; use with caution in severe hepatic impairment due to potential increased systemic exposure. |
| Pediatric use | Children 6-12 years: 1 spray (42 mcg) in each nostril twice daily. Children >12 years: same as adult dosing. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential increased sensitivity. |
| 1st trimester | Insufficient human data; based on animal studies, no evidence of teratogenicity. Use only if potential benefit justifies risk. |
| 2nd trimester | No known risks in humans; intranasal corticosteroids are generally considered safe. Use only if clearly needed. |
| 3rd trimester | No known risks in humans; intranasal corticosteroids are generally considered safe. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for BECONASE AQ (BECONASE AQ).
| Placental transfer | Very low; beclomethasone dipropionate undergoes extensive first-pass metabolism; minimal systemic absorption after intranasal use. |
| Breastfeeding | Inhaled or intranasal corticosteroids are excreted in breast milk in negligible amounts; unlikely to affect nursing infant. Use with caution. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to beclomethasone dipropionate or any componentUntreated nasal mucosal infection
| Precautions | Nasal septal perforation, Impaired wound healing, Cushing's syndrome with excessive use, Hypothalamic-pituitary-adrenal axis suppression, Increased risk of infections, Glaucoma and cataracts, Growth suppression in children |
| Food/Dietary | No significant food-drug interactions. No dietary restrictions required. Avoid alcohol if it worsens allergic symptoms. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L2 (Safer) |
| Teratogenic Risk | Beclomethasone dipropionate (intranasal) is not associated with a significant increase in major malformations based on available data. First trimester: No evidence of teratogenic risk from epidemiological studies. Second/third trimester: No specific fetal risks reported with intranasal use; systemic absorption is minimal. However, maternal adrenal suppression may occur with high doses. Intranasal route limits systemic exposure, thus fetal risk is considered low. |
| Fetal Monitoring | No routine maternal or fetal monitoring specifically required. Monitor for signs of nasal irritation or systemic corticosteroid effects (e.g., adrenal suppression) with prolonged high-dose use. For pregnant women, no special fetal monitoring needed beyond standard prenatal care. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies show no impairment of fertility at clinically relevant doses. Minimal systemic absorption suggests negligible impact on reproductive function. |
| Beconase AQ (beclomethasone dipropionate) is an intranasal corticosteroid for allergic rhinitis. Priming the pump with 6-7 actuations is required before first use or after a period of non-use >1 week. It may take up to 1 week for full therapeutic effect. Avoid spraying directly onto the nasal septum to reduce irritation. Can be used safely with oral antihistamines. Use with caution in patients with recent nasal ulcers, surgery, or trauma. |
| Patient Advice | Shake the bottle gently before each use. · Prime the pump by actuating 6-7 times into air before first use or if not used for more than 1 week. · Blow your nose gently to clear nostrils before use. · Insert nozzle into nostril, tilt head slightly forward, and spray away from the septum. · Do not exceed the recommended dose; it will not improve symptoms faster. · Rinse the nozzle with warm water after each use and replace cap tightly. · Benefits may take several days to develop; continue regular use. · Avoid getting the spray into your eyes; if contact occurs, rinse with water. · Do not use if you have an untreated nasal infection or recent nasal surgery. · Report symptoms of nasal bleeding, pain, or crusting to your doctor. |